151 |
CAS Should Replace CEA in Patients Eligible for Bypass Surgery with Multilevel Atherosclerosis |
Piotr Odrowaz-Pieniazek |
Apr. 21. 16 |
150 |
Does Carotid Stent Cell Design Matter?: Open vs. Closed vs. Micromesh |
Mark W. Burket |
Apr. 21. 16 |
149 |
Tailored Carotid Protection: Matching the Device to the Patient |
Jae-Hwan Lee |
Apr. 21. 16 |
148 |
Turn to Starting Line - Which Strategy for Whom?: CAS vs. CEA vs. Medical Therapy |
Robert Bersin |
Apr. 21. 16 |
147 |
A Novel Sirolimus Drug Coated Balloon Technology |
Robert Bersin |
Apr. 21. 16 |
146 |
How to Optimize Drug-Coated Balloon in Femoropopliteal Lesions |
Young-Guk Ko |
Apr. 21. 16 |
145 |
Overcome the Calcified Plaque Using Endovascular Therapy |
Kazushi Urasawa |
Apr. 21. 16 |
144 |
Show Me the Road: Randomized Trials of Antiproliferative Therapies: Zilver PTX, LEVANT II, In.PACT SFA and DEFINITIVE AR |
Ravish Sachar |
Apr. 21. 16 |
143 |
Updated Evidences of DCB from Real-World Registries |
Lawrence A. Garcia |
Apr. 21. 16 |
142 |
IN.PACT Global Sub-Analysis on Asian Population |
Young-Guk Ko |
Apr. 21. 15 |